Oramed’s daughter company Oravax Medical is preparing to begin clinical trials of its new oral Covid-19 vaccine at Tel Aviv Sourasky Medical Center. This was stated by Oramed Pharmaceuticals CEO Nadav Kidron, as The Jerusalem Post reports.
“The protocol for the inaugural Phase I/II trial that the company hopes to move forward with at Sourasky would involve 24 volunteers who have not yet been inoculated with another vaccine. Half of the group would take one capsule and the other two. There is no placebo group because the goal is to measure the level of antibodies and other immunity indicators," Kidron explained.
"The new Oravax vaccine candidate targets three structural proteins of the novel coronavirus, as opposed to the single spike protein targeted via the current Moderna and Pfizer vaccines. Thus, it should be much more resistant to COVID-19 variants," the statement reads.
As it was reported earlier, American pharmaceutical company Moderna intends to create vaccines against other viruses, including HIV.